Zurich based CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue

blonca9
Sep 23, 2024
1 min read

Co-Founder & CEO Christian Leisner describes the M-gager platform and how it allows the company to have high specificity to targets, and even go after intracellular antigens displayed as small HLA peptides.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Zurich based CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight